Thyroid Cancers | Clinical

Task Force Recommends Active Surveillance for Many Low-Risk Papillary Thyroid Microcarcinoma Patients

November 19, 2020

Active surveillance can be a safe and appropriate management strategy for patients with T1aN0M0 low-risk papillary thyroid microcarcinoma, though the decision to use the strategy requires multidisciplinary teams and patient input, according to a new report.

Real-World Data Support Use of Multikinase Inhibitors in Differentiated Thyroid Cancer

October 20, 2020

In an interview with Targeted Oncology, Marcia Brose, MD, PhD, discussed the findings for the global, non-interventional study that assessed the use of sorafenib as treatment of patients with asymptomatic radioiodine-refractory differentiated thyroid cancer.

ESMO Data Show Benefit of Approved Thyroid Cancer Regimens in Select Patients

October 14, 2020

Across subsets of patients with thyroid cancer, an interesting collection of research was shared with oncologists during the 2020 European Society of Medical Oncology Virtual Congress, demonstrating improvement in outcomes for patients with thyroid cancers with newer and established approved regimens.